# UNH — baseline

## Metadata

ticker: UNH
arm: baseline
judge_prompt_version: v2
context_sha256: 397638fa1ebfafe32855c453fcc07a9bb744a200cd5a33c03988317e39b1b4d9
llm_calls: 7
llm_endpoints: anthropic
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 313, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.179, "latency_s_total": 4.179, "parse_failure": 0, "prompt_tokens": 3273, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 400, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.32, "latency_s_total": 4.32, "parse_failure": 0, "prompt_tokens": 3261, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 187, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.114, "latency_s_total": 2.114, "parse_failure": 0, "prompt_tokens": 803, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 155, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.121, "latency_s_total": 2.121, "parse_failure": 0, "prompt_tokens": 796, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 196, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 1.863, "latency_s_total": 1.863, "parse_failure": 0, "prompt_tokens": 474, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 168, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 1.86, "latency_s_total": 1.86, "parse_failure": 0, "prompt_tokens": 395, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1173, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 16.445, "latency_s_total": 16.445, "parse_failure": 0, "prompt_tokens": 1818, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "UNH",
  "company_name": "UnitedHealth Group Incorporated",
  "current_price": 371.9,
  "currency": "USD",
  "market_cap": 333815513088.0,
  "pe_ratio": 23.916397,
  "forward_pe": 16.448336,
  "week_52_high": 461.62,
  "week_52_low": 255.97,
  "revenue": 450525986816.0,
  "net_income": 14122000384.0,
  "profit_margin": 0.03135,
  "dividend_yield": 2.5,
  "sector": "Healthcare",
  "industry": "Healthcare Plans"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-02",
    "summary": "ITEM 1A. RISK FACTORS CAUTIONARY STATEMENTS The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the \u201csafe harbor\u201d provisions of the PSLRA"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "ITEM 1A. RISK FACTORS In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, \u201cRisk Factors\u201d of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes to the risk factors as disclosed in our 2025 10-K. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities (a) Second Quarter 2026 For the Month Ended Total Number of Shares Pu"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] I cannot provide a summary of the latest 10-K and 10-Q based on the information provided. The context materials only contain excerpts from a 10-K filing focused specifically on risk factors related to UNH (UnitedHealth Group), not a comprehensive overview of the full 10-K or any 10-Q filing.

The available information addresses several key risk areas:

**Medical Cost Management Risks**: The company faces challenges in accurately predicting and pricing for medical costs, as risk-based products represent nearly 80% of total revenues. Small variances between predicted and actual costs can significantly impact financial results.

**Cybersecurity and Data Security Risks**: The company processes large amounts of sensitive data and faces ongoing cybersecurity threats, including a 2024 cyberattack on the Change Healthcare business. Data breaches could result in operational disruptions, financial losses, and reputational harm.

**Technology and Systems Integration Risks**: The company must successfully consolidate and integrate information systems while keeping pace with evolving technologies, including AI. Failures in these areas could result in higher costs and operational problems.

**Regulatory and Compliance Risks**: Rapidly evolving regulations related to health data, information technology, and AI may impose new compliance requirements and affect competitive positioning.

To obtain a complete summary of the latest 10-K and 10-Q filings, you would need to review the full documents directly from SEC EDGAR.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors related to its business operations:

## Medical Cost Management and Pricing Risks
The company faces substantial risks related to accurately estimating, pricing, and managing medical costs for risk-based products. Since premium revenues from risk-based products constitute nearly 80% of total consolidated revenues, small differences between predicted and actual medical costs can result in significant changes to financial results. Various factors may cause actual costs to exceed estimates, including medical cost inflation, increased service utilization, provider billing intensity, pandemics, new drug introductions or price increases, new treatment guidelines, regulatory changes, and climate change effects.

## Information Systems and Technology Risks
The company depends heavily on the integrity and availability of its data and information systems. Risks include potential failures in health, wellness, and technology products if data proves inaccurate or systems are not properly maintained. The company also faces challenges in consolidating, integrating, and upgrading existing information systems, as well as keeping pace with rapidly evolving technology, including artificial intelligence applications.

## Cybersecurity and Data Security Risks
The company regularly processes large amounts of sensitive data, including protected personal information and proprietary information. It faces ongoing risks from cyberattacks, data breaches, and security incidents that could result in operational disruptions, loss of revenue, increased costs, regulatory penalties, reputational harm, and litigation. The company previously experienced a cyberattack affecting its Change Healthcare business.

## Regulatory and Compliance Risks
Uncertain and rapidly evolving laws and regulations related to health data and health information technologies, including those involving artificial intelligence, may alter the competitive landscape and impose new compliance requirements.

## Business Relationship Risks
The company must maintain satisfactory relationships with health care payers, physicians, hospitals, and other service providers to sustain its business operations.

## Pre-written sections (judge input)

### Financial Health

UnitedHealth Group trades at $371.90 with a substantial market capitalization of $333.8 billion, reflecting its position as a healthcare industry leader. The company generated $450.5 billion in revenue with a net profit margin of 3.1%, demonstrating solid operational scale though modest profitability typical of managed care businesses. The current P/E ratio of 23.9x appears elevated relative to the forward P/E of 16.4x, suggesting market expectations for earnings growth ahead. With a 2.5% dividend yield and recent 52-week trading range of $255.97–$461.62, UNH exhibits both income appeal and significant volatility. Overall, the company presents a financially stable profile with strong revenue generation, though investors should monitor margin pressures and regulatory risks disclosed in recent SEC filings.

### Recent Developments

UnitedHealth Group's most recent SEC filings show no material changes to previously disclosed risk factors as of the second quarter 2026, suggesting stable operational conditions. The company continues to execute share repurchase programs, demonstrating management confidence in its valuation despite the stock trading near mid-range levels within its 52-week band. With a forward P/E of 16.4x and a 2.5% dividend yield, UNH appears reasonably valued relative to its healthcare sector peers, though investors should monitor regulatory and competitive pressures inherent to the healthcare plans industry. The absence of significant new developments in recent filings suggests the company is maintaining its strategic course without major operational disruptions.

### SEC Filing Highlights

UnitedHealth Group faces significant medical cost management challenges, with risk-based products comprising nearly 80% of revenues, making the company highly sensitive to variances between predicted and actual medical costs. The company experienced a notable 2024 cyberattack on its Change Healthcare business, underscoring ongoing cybersecurity risks associated with processing large volumes of sensitive healthcare data. Technology integration remains a critical priority as UNH consolidates information systems and adapts to emerging technologies including artificial intelligence. Regulatory pressures are intensifying around health data privacy, IT compliance, and AI governance, potentially affecting operational costs and competitive positioning. These factors collectively highlight the importance of operational execution, cybersecurity resilience, and regulatory compliance to UNH's financial performance and shareholder value.

### Risk Factors

• **Medical Cost Management Risk**: With risk-based products representing ~80% of consolidated revenues, small variances between predicted and actual medical costs can significantly impact financial results. Actual costs may exceed estimates due to medical inflation, increased utilization, new drug introductions, pandemics, and regulatory changes.

• **Cybersecurity and Data Security Risk**: UnitedHealth processes large volumes of sensitive personal and proprietary data, creating exposure to cyberattacks, breaches, and operational disruptions. Incidents could result in revenue loss, regulatory penalties, reputational damage, and litigation (the company previously experienced a cyberattack affecting its Change Healthcare business).

• **Information Systems and Technology Risk**: The company's dependence on data integrity and system availability creates risks related to product failures, system integration challenges, and the need to keep pace with rapidly evolving technology, including artificial intelligence applications.

## Audited (Exec Summary + Outlook)

### Executive Summary
UnitedHealth Group is a healthcare industry leader generating $450.5 billion in revenue with a market capitalization of $333.8 billion, operating primarily through risk-based managed care products that account for nearly 80% of consolidated revenues. The stock is notable now because the gap between its current P/E of 23.9x and forward P/E of 16.4x implies meaningful expected earnings growth, yet the wide 52-week trading range of $255.97–$461.62 reflects the significant uncertainty investors are pricing around that path. The single most important near-term variable is medical cost management: given the concentration of revenues in risk-based products, any sustained divergence between predicted and actual medical costs would have an outsized and immediate impact on profitability.

### Outlook
The directional outlook for UNH is **cautiously constructive**, supported by the company's scale, ongoing share repurchase activity, a dividend yield that provides income support, and the absence of material new risk disclosures through the second quarter of 2026. The primary tailwind is the implied earnings growth embedded in the spread between the current and forward P/E, which, if realized, would validate the current valuation and reward patient investors. However, several headwinds temper conviction: the medical cost trend remains the dominant variable to watch, as any acceleration in utilization, medical inflation, or adverse claims experience could compress the already-thin net profit margin characteristic of managed care businesses. Investors should also monitor the trajectory of cybersecurity remediation and resilience efforts following the Change Healthcare incident, the pace and cost of technology integration and AI governance compliance, and the evolving regulatory environment around health data privacy and IT compliance. The thesis would strengthen if medical cost ratios remain well-controlled, regulatory developments prove manageable, and the company demonstrates progress in technology modernization without material disruption; it would weaken if medical costs surprise to the upside, a new cybersecurity incident emerges, or regulatory actions impose meaningful incremental costs on operations.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "$450.5 billion in revenue"
LABEL: SUPPORTED
REASON: Source data shows revenue of $450,525,986,816, which rounds to $450.5 billion; the pre-written Financial Health section also states "$450.5 billion in revenue."

---

CLAIM: "market capitalization of $333.8 billion"
LABEL: SUPPORTED
REASON: Source data shows market_cap of $333,815,513,088, which rounds to $333.8 billion; confirmed in the pre-written Financial Health section.

---

CLAIM: "nearly 80% of consolidated revenues"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights, RAG Risk Factors, and pre-written SEC Filing Highlights and Risk Factors sections all explicitly state risk-based products constitute "nearly 80% of total consolidated revenues" / "nearly 80% of revenues."

---

CLAIM: "current P/E of 23.9x"
LABEL: SUPPORTED
REASON: Source data shows pe_ratio of 23.916397, which rounds to 23.9x; confirmed in the pre-written Financial Health section.

---

CLAIM: "forward P/E of 16.4x"
LABEL: SUPPORTED
REASON: Source data shows forward_pe of 16.448336, which rounds to 16.4x; confirmed in the pre-written Financial Health section.

---

CLAIM: "52-week trading range of $255.97–$461.62"
LABEL: SUPPORTED
REASON: Source data explicitly shows week_52_low of $255.97 and week_52_high of $461.62; confirmed in the pre-written Financial Health section.

---

**OUTLOOK**

---

CLAIM: "ongoing share repurchase activity"
LABEL: SUPPORTED
REASON: The 10-Q filing summary references "Issuer Purchases of Equity Securities" for Second Quarter 2026, and the pre-written Recent Developments section explicitly states "the company continues to execute share repurchase programs."

---

CLAIM: "a dividend yield that provides income support"
LABEL: SUPPORTED
REASON: Source data shows dividend_yield of 2.5%; the pre-written Financial Health and Recent Developments sections both reference the 2.5% dividend yield.

---

CLAIM: "absence of material new risk disclosures through the second quarter of 2026"
LABEL: SUPPORTED
REASON: The 10-Q filing summary (filed 2026-08-10, covering Second Quarter 2026) explicitly states "There have been no material changes to the risk factors as disclosed in our 2025 10-K," and the pre-written Recent Developments section restates this directly.

---

CLAIM: "the spread between the current and forward P/E" (as the implied earnings growth tailwind)
LABEL: INFERENCE
REASON: Both P/E figures (23.9x current, 16.4x forward) are present in the source data; the directional inference that a lower forward P/E implies expected earnings growth is a standard, single-step financial derivation from those two figures.

---

CLAIM: "already-thin net profit margin characteristic of managed care businesses"
LABEL: SUPPORTED
REASON: Source data shows profit_margin of 0.03135 (3.1%); the pre-written Financial Health section describes it as a "net profit margin of 3.1%" and notes it is "modest profitability typical of managed care businesses."

---

CLAIM: "the Change Healthcare incident" (cybersecurity reference)
LABEL: SUPPORTED
REASON: The RAG SEC Highlights, RAG Risk Factors, and pre-written SEC Filing Highlights and Risk Factors sections all explicitly reference "a 2024 cyberattack on its Change Healthcare business."

---

*No additional quantitative figures, price targets, thresholds, ratios, named product milestones, or forward-looking numbers appear in the Outlook section beyond those evaluated above.*
